Evaluation of characteristic metabolites of aromatic amino acids in patients with HIV infection at different stages of disease
Background Acquired immune deficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection, and antiretroviral therapy are usually associated with metabolic disorders. Screening for biomarkers to evaluate the progression of metabolic disorders is important for the diagnosis and treatment of...
Gespeichert in:
Veröffentlicht in: | Journal of clinical laboratory analysis 2023-01, Vol.37 (1), p.e24795-n/a |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | n/a |
---|---|
container_issue | 1 |
container_start_page | e24795 |
container_title | Journal of clinical laboratory analysis |
container_volume | 37 |
creator | Yuan, Zhong‐Wen Gan, Hai‐Ling Jin, Hong‐Liu Feng, Xiao‐Ying Wang, Ming Zhou, Hua‐Ping Zhang, Jing |
description | Background
Acquired immune deficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection, and antiretroviral therapy are usually associated with metabolic disorders. Screening for biomarkers to evaluate the progression of metabolic disorders is important for the diagnosis and treatment of HIV infection. This study aimed to establish and validate a method to quantify serum aromatic amino acid (AAA) metabolites as biomarkers of metabolic disorders in patients with HIV.
Methods
The AAAs and metabolites were analyzed using high‐performance liquid chromatography–tandem mass spectrometry. Pearson's correlation, heatmap, and receiver operating characteristic curve analyses were used for statistical analysis.
Results
Under optimal detection conditions, the lower limits of phenylalanine (Phe), tryptophan (Trp), kynurenine (Kyn), tyrosine, phenylacetylglutamine (PAGln), and 5‐hydroxytryptamine quantification reached 0.02, 0.02, 0.01, 0.02, 0.01, and 0.002 μg/ml, respectively, and the precision of intra‐ and inter‐day was stay below 10.30%. Serum samples were stable for at least 6 months when stored at −80°C. The inter‐group differences and associations between the biomarkers exhibited a particular volatility trend in PAGln, Trp, and Kyn metabolism in HIV‐infected patients with metabolic syndrome.
Conclusions
The developed method can be used for rapid and sensitive quantification of the AAA metabolism profile in vivo to further appraise the process of HIV infection, evaluate intervening measures, conduct mechanistic investigations, and further study the utility of PAGln, a characteristic metabolite of AAA, as a biomarker of HIV infection coupled with metabolic syndrome.
Acquired immunoeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection, and antiretroviral therapy are usually associated with metabolic disorders. Screening for biomarkers to evaluate the progression of metabolic disorders is important for the diagnosis and treatment of HIV infection. Aromatic amino acids (AAA) and metabolites mainly including tyrosine, phenylalanine (Phe), and tryptophan (Trp), kynurenine and 5‐hydroxytryptamine. In addition, the intestinal flora was able to break down Trp and Phe, and generate indole, indolic acid, skatole, tryptamine, phenylpyruvic acid, and phenyl acetic acid. Phenylacetic acid can be converted to phenyl acetylglutamine (PAGln) under the action of Gln PA‐transferase in liver, which have been confirmed closely related to cardiovascular d |
doi_str_mv | 10.1002/jcla.24795 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2747008313</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2763820779</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3935-e330c3418abe3c4966e1f2b483b757f5b500acb382cbb8ac6e2f5a349a1e62eb3</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhi1E1W5LL_wAZIkLQkrxRxI7x2pVaNFKXIBrNPaOqVdJvNhOq1747XiblgOHniy9fvTMaF5C3nJ2wRkTn3Z2gAtRq655RVacdboSWjSvyYpprSrNuDwhpyntGGO64-0xOZFt3dZKyxX5c3UHwwzZh4kGR-0tRLAZo0_ZWzpiBhMGnzEdfiGGEQ45jH4KFKzfJuonui8hTjnRe59v6fXNzxI6tI9SyHTrncNYAJoy_FpUW58QEr4hRw6GhOdP7xn58fnq-_q62nz7crO-3FRWdrKpUEpmZc01GJS27toWuROm1tKoRrnGNIyBNVILa4wG26JwDci6A46tQCPPyIfFu4_h94wp96NPFocBJgxz6oWqVbmO5LKg7_9Dd2GOU9muUG0ZwZTqCvVxoWwMKUV0_T76EeJDz1l_aKU_tNI_tlLgd0_K2Yy4_Yc-11AAvgD3fsCHF1T91_XmcpH-BRPKmN4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2763820779</pqid></control><display><type>article</type><title>Evaluation of characteristic metabolites of aromatic amino acids in patients with HIV infection at different stages of disease</title><source>MEDLINE</source><source>Wiley Online Library Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Yuan, Zhong‐Wen ; Gan, Hai‐Ling ; Jin, Hong‐Liu ; Feng, Xiao‐Ying ; Wang, Ming ; Zhou, Hua‐Ping ; Zhang, Jing</creator><creatorcontrib>Yuan, Zhong‐Wen ; Gan, Hai‐Ling ; Jin, Hong‐Liu ; Feng, Xiao‐Ying ; Wang, Ming ; Zhou, Hua‐Ping ; Zhang, Jing</creatorcontrib><description>Background
Acquired immune deficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection, and antiretroviral therapy are usually associated with metabolic disorders. Screening for biomarkers to evaluate the progression of metabolic disorders is important for the diagnosis and treatment of HIV infection. This study aimed to establish and validate a method to quantify serum aromatic amino acid (AAA) metabolites as biomarkers of metabolic disorders in patients with HIV.
Methods
The AAAs and metabolites were analyzed using high‐performance liquid chromatography–tandem mass spectrometry. Pearson's correlation, heatmap, and receiver operating characteristic curve analyses were used for statistical analysis.
Results
Under optimal detection conditions, the lower limits of phenylalanine (Phe), tryptophan (Trp), kynurenine (Kyn), tyrosine, phenylacetylglutamine (PAGln), and 5‐hydroxytryptamine quantification reached 0.02, 0.02, 0.01, 0.02, 0.01, and 0.002 μg/ml, respectively, and the precision of intra‐ and inter‐day was stay below 10.30%. Serum samples were stable for at least 6 months when stored at −80°C. The inter‐group differences and associations between the biomarkers exhibited a particular volatility trend in PAGln, Trp, and Kyn metabolism in HIV‐infected patients with metabolic syndrome.
Conclusions
The developed method can be used for rapid and sensitive quantification of the AAA metabolism profile in vivo to further appraise the process of HIV infection, evaluate intervening measures, conduct mechanistic investigations, and further study the utility of PAGln, a characteristic metabolite of AAA, as a biomarker of HIV infection coupled with metabolic syndrome.
Acquired immunoeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection, and antiretroviral therapy are usually associated with metabolic disorders. Screening for biomarkers to evaluate the progression of metabolic disorders is important for the diagnosis and treatment of HIV infection. Aromatic amino acids (AAA) and metabolites mainly including tyrosine, phenylalanine (Phe), and tryptophan (Trp), kynurenine and 5‐hydroxytryptamine. In addition, the intestinal flora was able to break down Trp and Phe, and generate indole, indolic acid, skatole, tryptamine, phenylpyruvic acid, and phenyl acetic acid. Phenylacetic acid can be converted to phenyl acetylglutamine (PAGln) under the action of Gln PA‐transferase in liver, which have been confirmed closely related to cardiovascular disease. This study also attempts to explore the level changes of AAA metabolic, especially PAGln. This study aimed to establish and validate a method to quantify serum AAA metabolites as biomarkers of metabolic disorders in patients with HIV. The developed method can be used for rapid and sensitive quantification of the AAA metabolism profile in vivo to further appraise the process of HIV infection, evaluate intervening measures, conduct mechanistic investigations, and further study the utility of PAGln, a characteristic metabolite of AAA, as a biomarker of HIV infection coupled with metabolic syndrome.</description><identifier>ISSN: 0887-8013</identifier><identifier>EISSN: 1098-2825</identifier><identifier>DOI: 10.1002/jcla.24795</identifier><identifier>PMID: 36464783</identifier><language>eng</language><publisher>United States: John Wiley & Sons, Inc</publisher><subject>Acquired immune deficiency syndrome ; AIDS ; Amino acids ; Amino Acids, Aromatic ; Antiretroviral therapy ; aromatic amino acid metabolites ; Biomarkers ; Body mass index ; Diabetes ; High-performance liquid chromatography ; high‐performance liquid chromatography–tandem mass spectrometry ; HIV ; HIV Infections ; Human immunodeficiency virus ; Humans ; Infections ; Infectious diseases ; Insulin resistance ; Lipids ; Mass spectroscopy ; metabolic disorder ; Metabolic disorders ; Metabolic Syndrome ; Metabolites ; Microbiota ; phenylacetylglutamine ; Phenylalanine ; Statistical analysis ; Tandem Mass Spectrometry - methods ; Tryptophan ; Tyrosine</subject><ispartof>Journal of clinical laboratory analysis, 2023-01, Vol.37 (1), p.e24795-n/a</ispartof><rights>2022 The Authors. published by Wiley Periodicals LLC.</rights><rights>2022 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.</rights><rights>2023. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3935-e330c3418abe3c4966e1f2b483b757f5b500acb382cbb8ac6e2f5a349a1e62eb3</citedby><cites>FETCH-LOGICAL-c3935-e330c3418abe3c4966e1f2b483b757f5b500acb382cbb8ac6e2f5a349a1e62eb3</cites><orcidid>0000-0003-3443-4723</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjcla.24795$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjcla.24795$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,860,1411,11541,27901,27902,45550,45551,46027,46451</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36464783$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yuan, Zhong‐Wen</creatorcontrib><creatorcontrib>Gan, Hai‐Ling</creatorcontrib><creatorcontrib>Jin, Hong‐Liu</creatorcontrib><creatorcontrib>Feng, Xiao‐Ying</creatorcontrib><creatorcontrib>Wang, Ming</creatorcontrib><creatorcontrib>Zhou, Hua‐Ping</creatorcontrib><creatorcontrib>Zhang, Jing</creatorcontrib><title>Evaluation of characteristic metabolites of aromatic amino acids in patients with HIV infection at different stages of disease</title><title>Journal of clinical laboratory analysis</title><addtitle>J Clin Lab Anal</addtitle><description>Background
Acquired immune deficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection, and antiretroviral therapy are usually associated with metabolic disorders. Screening for biomarkers to evaluate the progression of metabolic disorders is important for the diagnosis and treatment of HIV infection. This study aimed to establish and validate a method to quantify serum aromatic amino acid (AAA) metabolites as biomarkers of metabolic disorders in patients with HIV.
Methods
The AAAs and metabolites were analyzed using high‐performance liquid chromatography–tandem mass spectrometry. Pearson's correlation, heatmap, and receiver operating characteristic curve analyses were used for statistical analysis.
Results
Under optimal detection conditions, the lower limits of phenylalanine (Phe), tryptophan (Trp), kynurenine (Kyn), tyrosine, phenylacetylglutamine (PAGln), and 5‐hydroxytryptamine quantification reached 0.02, 0.02, 0.01, 0.02, 0.01, and 0.002 μg/ml, respectively, and the precision of intra‐ and inter‐day was stay below 10.30%. Serum samples were stable for at least 6 months when stored at −80°C. The inter‐group differences and associations between the biomarkers exhibited a particular volatility trend in PAGln, Trp, and Kyn metabolism in HIV‐infected patients with metabolic syndrome.
Conclusions
The developed method can be used for rapid and sensitive quantification of the AAA metabolism profile in vivo to further appraise the process of HIV infection, evaluate intervening measures, conduct mechanistic investigations, and further study the utility of PAGln, a characteristic metabolite of AAA, as a biomarker of HIV infection coupled with metabolic syndrome.
Acquired immunoeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection, and antiretroviral therapy are usually associated with metabolic disorders. Screening for biomarkers to evaluate the progression of metabolic disorders is important for the diagnosis and treatment of HIV infection. Aromatic amino acids (AAA) and metabolites mainly including tyrosine, phenylalanine (Phe), and tryptophan (Trp), kynurenine and 5‐hydroxytryptamine. In addition, the intestinal flora was able to break down Trp and Phe, and generate indole, indolic acid, skatole, tryptamine, phenylpyruvic acid, and phenyl acetic acid. Phenylacetic acid can be converted to phenyl acetylglutamine (PAGln) under the action of Gln PA‐transferase in liver, which have been confirmed closely related to cardiovascular disease. This study also attempts to explore the level changes of AAA metabolic, especially PAGln. This study aimed to establish and validate a method to quantify serum AAA metabolites as biomarkers of metabolic disorders in patients with HIV. The developed method can be used for rapid and sensitive quantification of the AAA metabolism profile in vivo to further appraise the process of HIV infection, evaluate intervening measures, conduct mechanistic investigations, and further study the utility of PAGln, a characteristic metabolite of AAA, as a biomarker of HIV infection coupled with metabolic syndrome.</description><subject>Acquired immune deficiency syndrome</subject><subject>AIDS</subject><subject>Amino acids</subject><subject>Amino Acids, Aromatic</subject><subject>Antiretroviral therapy</subject><subject>aromatic amino acid metabolites</subject><subject>Biomarkers</subject><subject>Body mass index</subject><subject>Diabetes</subject><subject>High-performance liquid chromatography</subject><subject>high‐performance liquid chromatography–tandem mass spectrometry</subject><subject>HIV</subject><subject>HIV Infections</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Insulin resistance</subject><subject>Lipids</subject><subject>Mass spectroscopy</subject><subject>metabolic disorder</subject><subject>Metabolic disorders</subject><subject>Metabolic Syndrome</subject><subject>Metabolites</subject><subject>Microbiota</subject><subject>phenylacetylglutamine</subject><subject>Phenylalanine</subject><subject>Statistical analysis</subject><subject>Tandem Mass Spectrometry - methods</subject><subject>Tryptophan</subject><subject>Tyrosine</subject><issn>0887-8013</issn><issn>1098-2825</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kU1v1DAQhi1E1W5LL_wAZIkLQkrxRxI7x2pVaNFKXIBrNPaOqVdJvNhOq1747XiblgOHniy9fvTMaF5C3nJ2wRkTn3Z2gAtRq655RVacdboSWjSvyYpprSrNuDwhpyntGGO64-0xOZFt3dZKyxX5c3UHwwzZh4kGR-0tRLAZo0_ZWzpiBhMGnzEdfiGGEQ45jH4KFKzfJuonui8hTjnRe59v6fXNzxI6tI9SyHTrncNYAJoy_FpUW58QEr4hRw6GhOdP7xn58fnq-_q62nz7crO-3FRWdrKpUEpmZc01GJS27toWuROm1tKoRrnGNIyBNVILa4wG26JwDci6A46tQCPPyIfFu4_h94wp96NPFocBJgxz6oWqVbmO5LKg7_9Dd2GOU9muUG0ZwZTqCvVxoWwMKUV0_T76EeJDz1l_aKU_tNI_tlLgd0_K2Yy4_Yc-11AAvgD3fsCHF1T91_XmcpH-BRPKmN4</recordid><startdate>202301</startdate><enddate>202301</enddate><creator>Yuan, Zhong‐Wen</creator><creator>Gan, Hai‐Ling</creator><creator>Jin, Hong‐Liu</creator><creator>Feng, Xiao‐Ying</creator><creator>Wang, Ming</creator><creator>Zhou, Hua‐Ping</creator><creator>Zhang, Jing</creator><general>John Wiley & Sons, Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PIMPY</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3443-4723</orcidid></search><sort><creationdate>202301</creationdate><title>Evaluation of characteristic metabolites of aromatic amino acids in patients with HIV infection at different stages of disease</title><author>Yuan, Zhong‐Wen ; Gan, Hai‐Ling ; Jin, Hong‐Liu ; Feng, Xiao‐Ying ; Wang, Ming ; Zhou, Hua‐Ping ; Zhang, Jing</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3935-e330c3418abe3c4966e1f2b483b757f5b500acb382cbb8ac6e2f5a349a1e62eb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Acquired immune deficiency syndrome</topic><topic>AIDS</topic><topic>Amino acids</topic><topic>Amino Acids, Aromatic</topic><topic>Antiretroviral therapy</topic><topic>aromatic amino acid metabolites</topic><topic>Biomarkers</topic><topic>Body mass index</topic><topic>Diabetes</topic><topic>High-performance liquid chromatography</topic><topic>high‐performance liquid chromatography–tandem mass spectrometry</topic><topic>HIV</topic><topic>HIV Infections</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Insulin resistance</topic><topic>Lipids</topic><topic>Mass spectroscopy</topic><topic>metabolic disorder</topic><topic>Metabolic disorders</topic><topic>Metabolic Syndrome</topic><topic>Metabolites</topic><topic>Microbiota</topic><topic>phenylacetylglutamine</topic><topic>Phenylalanine</topic><topic>Statistical analysis</topic><topic>Tandem Mass Spectrometry - methods</topic><topic>Tryptophan</topic><topic>Tyrosine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yuan, Zhong‐Wen</creatorcontrib><creatorcontrib>Gan, Hai‐Ling</creatorcontrib><creatorcontrib>Jin, Hong‐Liu</creatorcontrib><creatorcontrib>Feng, Xiao‐Ying</creatorcontrib><creatorcontrib>Wang, Ming</creatorcontrib><creatorcontrib>Zhou, Hua‐Ping</creatorcontrib><creatorcontrib>Zhang, Jing</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Biological Science Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied & Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical laboratory analysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yuan, Zhong‐Wen</au><au>Gan, Hai‐Ling</au><au>Jin, Hong‐Liu</au><au>Feng, Xiao‐Ying</au><au>Wang, Ming</au><au>Zhou, Hua‐Ping</au><au>Zhang, Jing</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of characteristic metabolites of aromatic amino acids in patients with HIV infection at different stages of disease</atitle><jtitle>Journal of clinical laboratory analysis</jtitle><addtitle>J Clin Lab Anal</addtitle><date>2023-01</date><risdate>2023</risdate><volume>37</volume><issue>1</issue><spage>e24795</spage><epage>n/a</epage><pages>e24795-n/a</pages><issn>0887-8013</issn><eissn>1098-2825</eissn><abstract>Background
Acquired immune deficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection, and antiretroviral therapy are usually associated with metabolic disorders. Screening for biomarkers to evaluate the progression of metabolic disorders is important for the diagnosis and treatment of HIV infection. This study aimed to establish and validate a method to quantify serum aromatic amino acid (AAA) metabolites as biomarkers of metabolic disorders in patients with HIV.
Methods
The AAAs and metabolites were analyzed using high‐performance liquid chromatography–tandem mass spectrometry. Pearson's correlation, heatmap, and receiver operating characteristic curve analyses were used for statistical analysis.
Results
Under optimal detection conditions, the lower limits of phenylalanine (Phe), tryptophan (Trp), kynurenine (Kyn), tyrosine, phenylacetylglutamine (PAGln), and 5‐hydroxytryptamine quantification reached 0.02, 0.02, 0.01, 0.02, 0.01, and 0.002 μg/ml, respectively, and the precision of intra‐ and inter‐day was stay below 10.30%. Serum samples were stable for at least 6 months when stored at −80°C. The inter‐group differences and associations between the biomarkers exhibited a particular volatility trend in PAGln, Trp, and Kyn metabolism in HIV‐infected patients with metabolic syndrome.
Conclusions
The developed method can be used for rapid and sensitive quantification of the AAA metabolism profile in vivo to further appraise the process of HIV infection, evaluate intervening measures, conduct mechanistic investigations, and further study the utility of PAGln, a characteristic metabolite of AAA, as a biomarker of HIV infection coupled with metabolic syndrome.
Acquired immunoeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection, and antiretroviral therapy are usually associated with metabolic disorders. Screening for biomarkers to evaluate the progression of metabolic disorders is important for the diagnosis and treatment of HIV infection. Aromatic amino acids (AAA) and metabolites mainly including tyrosine, phenylalanine (Phe), and tryptophan (Trp), kynurenine and 5‐hydroxytryptamine. In addition, the intestinal flora was able to break down Trp and Phe, and generate indole, indolic acid, skatole, tryptamine, phenylpyruvic acid, and phenyl acetic acid. Phenylacetic acid can be converted to phenyl acetylglutamine (PAGln) under the action of Gln PA‐transferase in liver, which have been confirmed closely related to cardiovascular disease. This study also attempts to explore the level changes of AAA metabolic, especially PAGln. This study aimed to establish and validate a method to quantify serum AAA metabolites as biomarkers of metabolic disorders in patients with HIV. The developed method can be used for rapid and sensitive quantification of the AAA metabolism profile in vivo to further appraise the process of HIV infection, evaluate intervening measures, conduct mechanistic investigations, and further study the utility of PAGln, a characteristic metabolite of AAA, as a biomarker of HIV infection coupled with metabolic syndrome.</abstract><cop>United States</cop><pub>John Wiley & Sons, Inc</pub><pmid>36464783</pmid><doi>10.1002/jcla.24795</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-3443-4723</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0887-8013 |
ispartof | Journal of clinical laboratory analysis, 2023-01, Vol.37 (1), p.e24795-n/a |
issn | 0887-8013 1098-2825 |
language | eng |
recordid | cdi_proquest_miscellaneous_2747008313 |
source | MEDLINE; Wiley Online Library Open Access; DOAJ Directory of Open Access Journals; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
subjects | Acquired immune deficiency syndrome AIDS Amino acids Amino Acids, Aromatic Antiretroviral therapy aromatic amino acid metabolites Biomarkers Body mass index Diabetes High-performance liquid chromatography high‐performance liquid chromatography–tandem mass spectrometry HIV HIV Infections Human immunodeficiency virus Humans Infections Infectious diseases Insulin resistance Lipids Mass spectroscopy metabolic disorder Metabolic disorders Metabolic Syndrome Metabolites Microbiota phenylacetylglutamine Phenylalanine Statistical analysis Tandem Mass Spectrometry - methods Tryptophan Tyrosine |
title | Evaluation of characteristic metabolites of aromatic amino acids in patients with HIV infection at different stages of disease |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T13%3A03%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20characteristic%20metabolites%20of%20aromatic%20amino%20acids%20in%20patients%20with%20HIV%20infection%20at%20different%20stages%20of%20disease&rft.jtitle=Journal%20of%20clinical%20laboratory%20analysis&rft.au=Yuan,%20Zhong%E2%80%90Wen&rft.date=2023-01&rft.volume=37&rft.issue=1&rft.spage=e24795&rft.epage=n/a&rft.pages=e24795-n/a&rft.issn=0887-8013&rft.eissn=1098-2825&rft_id=info:doi/10.1002/jcla.24795&rft_dat=%3Cproquest_cross%3E2763820779%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2763820779&rft_id=info:pmid/36464783&rfr_iscdi=true |